PTB (polypyrimidine tract-binding protein) is a repressive regulator of alternative splicing. We have investigated the role of PTB in three model alternative splicing systems. In the α-actinin gene, PTB represses the SM (smooth muscle) exon by binding to key sites in the polypyrimidine tract. Repressive binding to these sites is assisted by co-operative binding to additional downstream sites. SM exon splicing can be activated by CELF proteins, which also bind co-operatively to interspersed sites and displace PTB from the pyrimidine tract. Exon 11 of PTB pre-mRNA is repressed by PTB in an autoregulatory feedback loop. Exon 11-skipped RNA gets degraded through nonsense-mediated decay. Less than 1% of steady-state PTB mRNA is represented by this isoform, but inhibition of nonsense-mediated decay by RNA interference against Upf1 shows that at least 20% of PTB RNA is consumed by this pathway. This represents a widespread but under-appreciated role of alternative splicing in the quantitative regulation of gene expression, an important addition to its role as a generator of protein isoform diversity. Repression of α-tropomyosin exon 3 is an exceptional example of PTB regulation, because repression only occurs at high levels in SM cells, despite the fact that PTB is widely expressed. In this case, a PTB-interacting cofactor, raver1, appears to play an important role. By the use of 'tethering' assays, we have identified discrete domains within both PTB and raver1 that mediate their repressive activities on this splicing event.
Introduction
Alternative pre-mRNA splicing is a central mechanism of gene control in metazoan organisms. It allows the production of a much larger repertoire of functionally distinct proteins than was first suggested by the number of genes in the genomes [1, 2] , and also contributes to quantitative control by producing RNAs that are substrates for NMD (nonsensemediated decay) [3] . Regulation of alternative splicing decisions is mediated to a large extent by RNA-binding proteins in the SR (sarcoplasmic reticulum) and hnRNP (heterogeneous nuclear ribonucleoprotein) family of proteins [4, 5] . SR proteins contain one or two N-terminal RNAbinding domains of the RRM (RNA-recognition motif) class and a C-terminal domain rich in arginine and serine residues. SR proteins have a role in both constitutive and alternative splicings, usually acting as activators. hnRNP proteins contain RNA-binding domains of the RRM or K-homology class as well as various auxiliary domains. They have multiple cellular roles in pre-mRNA and mRNA metabolism [6, 7] and many of them are regulators of alternative splicing, usually acting as repressors. Dynamic antagonism between members of the SR and hnRNP protein families is believed to be Key words: alternative splicing, heterogeneous nuclear ribonucleoprotein (hnRNP), nonsensemediated decay, polypyrimidine tract-binding protein (PTB), RNA recognition motif, smooth muscle. Abbreviations used: CUG-BP, CUG-binding protein; hnRNP, heterogeneous nuclear ribonucleoprotein; NM, non-muscle; NMD, nonsense-mediated decay; PTB, polypyrimidine tract-binding protein; RRM, RNA-recognition motif; SM, smooth muscle; SR, sarcoplasmic reticulum; TM, α-tropomyosin. 1 To whom correspondence should be addressed (email cwjs1@cam.ac.uk).
important for determining a number of alternative splicing patterns [4, 5] .
We have worked on three model systems of regulated pre-mRNA splicing in which PTB (polypyrimidine tractbinding protein) acts as a regulator: the gene for PTB itself, α-actinin and TM (α-tropomyosin) ( Figure 1 ). PTB is a widely expressed hnRNP protein, also known as hnRNP-I, which acts as a repressive regulator of alternative splicing [8] . Structurally, PTB is composed of four RRM domains with interdomain linker regions and an N-terminal extension containing both nuclear localization and export signals. In addition to the most widespread form of PTB, mammals have two other paralogues, nPTB [9, 10] and ROD1 [11] , which show a more restricted expression in neurons and haematopoietic cells respectively. A fourth paralogue, smPTB, is expressed at high levels in SM (smooth muscle) cells of rats and mice, but is restricted to rodents [12] . PTB exon 11 skipping: alternative splicing that leads to degradation Exon 11 of the PTB gene is a cassette exon that can be included or skipped (Figure 1) . In HeLa cells, the observed steady-state levels of exon skipping are below 1%. However, exon 11 skipping leads to a frameshift and introduction of a premature stop codon in exon 12. Because there are three further exon-exon junctions >55 nt downstream of this stop codon, the RNA product is predicted to be a substrate for the NMD pathway [20] . Inhibition of NMD using siRNAs (small interfering RNAs) targeting various NMD factors reveals at least 20% of the PTB RNA to be spliced due to exon 11 skipping [21] (N. McGlincy and C.W.J. Smith, unpublished work). The rationale for this superficially wasteful splicing event is regulation. There are conserved PTB-binding sites within the 3 -half of exon 11 and between the exon and its branch point 351 nt upstream. Depletion of PTB from nuclear extracts in vitro and by RNAi (RNA interference) in HeLa cells ( Figure 2 ) resulted in the activation of exon 11 splicing. These effects of depletion could be more than fully reversed by the addition of recombinant PTB [21] . Therefore splicing of PTB exon 11 is sensitive to both increases and decreases in the levels of PTB, providing a simple autoregulatory loop to maintain the levels of PTB. This provides an experimentally well-defined example of what may be a very large pool of alternative splicing events whose primary purpose is quantitative gene control by targeting RNAs to NMD rather than production of protein isoforms [3] .
α-Actinin splicing: widespread repression by PTB
The α-actinin gene has a pair of alternative exons denoted NM (non-muscle) and SM [13] (Figure 1 ). The SM branch point sequence, involved in step 1 of the splicing reaction, is 386 nt upstream of the exon and only 55 nt downstream of the NM exon [14] . Within the polypyrimidine tract of the SM exon, there are two optimal binding sites for PTB [15] , and a further seven sites in the extended region down to the SM exon. A number of lines of evidence suggest that PTB is a repressor of the SM exon. Most convincingly, depletion of PTB from nuclear extract led to partial activation of SM exon splicing in vitro and repression was restored by the addition of recombinant PTB [14] . Notably, the presence of PTB- binding sites in the polypyrimidine tract alone is not sufficient to repress splicing, as demonstrated by the activation of splicing in vitro when the downstream PTB-binding sites are removed by transcript truncation. Using 'patch-labelled' RNA transcripts, in which cross-linking of proteins to the polypyrimidine tract can be observed in the presence or absence of downstream, covalently attached, unlabelled binding sites, we found that repression of splicing correlates with co-operative binding of PTB to the polypyrimidine tract (A. Matlin, J. Southby and C.W.J. Smith, unpublished work), a situation analogous to the repression of the N1 exon of c-src by co-operative PTB binding [16] . The SM exon is selected efficiently in SM and brain [13, 17] . This may arise as the result of dynamic antagonism between PTB and another group of hnRNP proteins, the CELF family [18] . CUG-BP (CUGbinding protein) and other members of the CELF protein family are capable of antagonizing PTB-mediated repression in vitro and in transfected cells [19] . There are many probable binding sites for CELF proteins between the SM pyrimidine tract and exon, but competitive binding of CUG-BP and PTB at adjacent sites at the 3 -end of the pyrimidine tract appears to be particularly important [19] . Actinin, therefore, represents a system in which the competition between different hnRNP proteins, PTB and CUG-BP, can determine the splicing outcome.
TM splicing: restricted repression by PTB
Exons 2 and 3 of the TM gene represent our bestcharacterized model system. The two exons are mutually exclusive due to the extreme proximity between the exon 3 branch point sequence and the 5 -splice site of exon 2 [22] . Exon 3 is selected in striated muscles and exon 2 in SM tissues [23, 24] . In transfected cells, exon 3 selection appears to be a 'default' choice [25] , although some NM tissues with low levels of TM RNA also show high proportions of exon 2 selection [24] . Exon 3 selection is generally favoured because it has stronger splice site elements than exon 2 [25] . In SM cells, exon 2 is selected as a result of repression of exon 3, mediated by flanking negative regulatory elements [15, [26] [27] [28] . On each side of exon 3, there are binding sites for PTB [15, 27] , as well as UGC/CUG repeat motifs [26, 28] . Multiple lines of evidence indicate the role of PTB as a repressor of TM exon 3, including the parallel effects of mutations on regulated splicing in vivo with effects on PTB binding in vitro [15, 27] , addition of excess PTB in vitro [29] , depletion and addback of PTB in vitro [30] and RNAi depletion in vivo (A. Rideau, R. Spellman and C.W.J. Smith, unpublished work). The two common isoforms of PTB, which differ by a 26-amino-acid insert in PTB4 compared with PTB1, show differential activity after TM splicing. Overexpressed PTB4 acts as a more potent repressor than PTB1 [30] . A particularly useful approach, which has subsequently facilitated structure-function analysis, is artificial recruitment [31] (Figure 3) . Replacement of the downstream PTB-binding site (referred to as 'DY') by binding sites for the MS2 bacteriophage coat protein results in deregulation of splicing. However, complete regulation of splicing is restored by the addition of a PTB-MS2 fusion protein; 'artificial recruitment' of PTB by the binding of MS2 coat protein to its binding site is sufficient to cause repression of exon 3. Because direct binding of PTB is no longer required, this has allowed us to make deletions within the PTB-MS2 fusion protein, leading to identification of RRM2 and the following linker as a minimal splicing repressor region of PTB (F. Robinson and C.W.J. Smith, unpublished work). The 26-amino-acid insert that distinguishes PTB4 from PTB1 is within the linker following RRM2, and intriguingly, this isoform-specific insert enhances the activity of the minimal repressor domain in this assay. Our future work will aim to identify the molecular target(s) of the repressor domain.
The TM model system is unusual among PTB-regulated splicing events in that PTB-mediated repression only occurs in a restricted cell type rather than being widespread; additional co-repressors are required. The protein raver1 appears to be such a co-repressor [31] . Originally discovered in yeast two-hybrid assays by its interaction with the cytoskeletal protein vinculin [32] , raver1 was subsequently found to interact and co-localize with PTB. When cotransfected with TM minigenes into PAC1 SM cells, raver1 In the reporter construct TM-MS2, the PTB-binding DY element has been replaced by two binding sites for the bacteriophage MS2 coat protein (indicated by the stem-loop symbols). The construct was transfected into PAC1 SM cells along with various MS2 fusion proteins and splicing patterns were analysed by RT-PCR using a radiolabelled PCR primer. PCR products were run on denaturing polyacrylamide gels and exposed to a phosphoimager. Fusion of PTB or raver1 to MS2 led to substantial exon skipping compared with MS2 alone. Fusion of the C-terminal amino acids 442-748 of raver1 but not the N-terminal amino acids 1-441 led to exon skipping, consistent with the C-terminal region possessing splicing repressor activity.
potently induced the skipping of exon 3, so that this became the predominant splicing pathway [31] . Although raver1 also induces skipping of other PTB-regulated exons, overexpressed raver1, in the actinin and PTB model systems, is less potent than PTB, whereas in the TM model system, it is more active than PTB. The influence of raver1 on TM splicing is dependent on the PTB-binding-regulatory elements, but not the UGC/CUG elements. MS2 recruitment of raver1, or just its C-terminal amino acids 442-748, was sufficient to repress exon 3 ( Figure 3 ). On the basis of the available evidence, we suggested that the role of PTB at the downstream site was to recruit raver1 (through RNA-PTB and PTB-raver1 interactions) and that the recruited Cterminal domain of raver1 then acted as a potent repressor of exon 3 [31] . Subsequent experiments have required us to re-evaluate this model. In particular, although the twohybrid data had indicated that PTB interacted with the N-terminal amino acids 1-441 of raver1 [32] , subsequent pull-down experiments have shown that at least three nonoverlapping parts of raver1, including the C-terminal region, can also interact independently with PTB (C. Gooding, A. Rideau and C.W.J. Smith, unpublished work). Therefore we cannot rule out the possibility that the artificially recruited C-terminal domain of raver1 may act, at least in part, by recruiting PTB. Analysis of various raver1 deletion mutants in the MS2 recruitment assay and in pull-down assays with GST-PTB indicates that interaction with PTB is necessary but not sufficient for the splicing repression action of the raver1 C-terminal region (A. Rideau, C. Gooding and C.W.J.
Smith, unpublished work). A future study will aim to identify the additional molecular targets of raver1 that are involved in its splicing-regulatory activity.
Mechanistically, TM is the most intriguing of our PTBregulated model systems. It is unique in that repression by PTB occurs in a restricted cell type, in the PTB4 > PTB1 hierarchy of repression and in the strong co-repression by raver1. It also provides another interesting example of an alternative splicing event that leads to NMD. The downstream DY element acts as the polypyrimidine tract of a cryptic exon, splicing of which can be strongly activated by a range of simple point mutations (S. Nagaraja-Grellscheid and C.W.J. Smith, unpublished work). Inclusion of the new exon introduces a premature stop codon and is predicted to lead to NMD. The ease with which splicing of this 'pseudoexon' can be activated, coupled with its conservation across several mammalian species, and the fact that it shows tissuespecific inclusion in transgenic animals [24] , suggests that this may be a genuine alternative splicing event. We are currently investigating whether this splicing event may play a role in quantitative regulation of TM expression.
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